Clinical Trials Directory

Trials / Completed

CompletedNCT00505167

Memantine Versus Donepezil in Early Stages of Alzheimer's Disease

Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
64 (actual)
Sponsor
Hospital Miguel Servet · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.

Detailed description

On the basis of the excess of glutamatergic stimulation, our objective is to demonstrate whether memantine could have a neuroprotective effect in Alzheimer's disease when administered in the early stages and in comparison to donepezil. The patients would be randomized to receive one of these drugs. At baseline we would evaluate the patients from a clinical standpoint with the ADAS-cog, the neuropsychiatric Inventory and a scale of daily living activities.We also would carry out Magnetic Resonance Spectroscopy in several areas of the brain (medial temporal lobe, prefrontal region, cingulate gyrus and occipital lobe) so as to measure the concentration of N-acetyl-aspartate which is a marker of neuronal density.Then we treat the patients with either memantine or denepezil and after 6 months we would repeat the same procedures as we did at baseline.

Conditions

Interventions

TypeNameDescription
DRUGMemantinePatients randomized to receive either memantine or donepezil
DRUGDonepezilPatients randomized to receive either memantine or donepezil

Timeline

Start date
2007-07-01
Primary completion
2008-07-01
Completion
2008-12-01
First posted
2007-07-23
Last updated
2008-12-29

Locations

3 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT00505167. Inclusion in this directory is not an endorsement.